InMed Pharmaceuticals (INM) Operating Leases (2021 - 2025)
Historic Operating Leases for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $215478.0.
- InMed Pharmaceuticals' Operating Leases fell 7963.43% to $215478.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $215478.0, marking a year-over-year decrease of 7963.43%. This contributed to the annual value of $305755.0 for FY2025, which is 5258.62% down from last year.
- As of Q3 2025, InMed Pharmaceuticals' Operating Leases stood at $215478.0, which was down 7963.43% from $305755.0 recorded in Q2 2025.
- Over the past 5 years, InMed Pharmaceuticals' Operating Leases peaked at $1.2 million during Q4 2023, and registered a low of $15994.0 during Q2 2023.
- Its 5-year average for Operating Leases is $479053.8, with a median of $389498.0 in 2022.
- Per our database at Business Quant, InMed Pharmaceuticals' Operating Leases crashed by 9589.37% in 2023 and then surged by 393191.82% in 2024.
- Quarter analysis of 5 years shows InMed Pharmaceuticals' Operating Leases stood at $825427.0 in 2021, then tumbled by 77.72% to $183902.0 in 2022, then surged by 534.56% to $1.2 million in 2023, then tumbled by 54.65% to $529248.0 in 2024, then plummeted by 59.29% to $215478.0 in 2025.
- Its last three reported values are $215478.0 in Q3 2025, $305755.0 for Q2 2025, and $419347.0 during Q1 2025.